These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 17868726)

  • 1. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
    J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
    J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
    J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturation technique does not decrease cancer detection during followup after initial prostate biopsy.
    Lane BR; Zippe CD; Abouassaly R; Schoenfield L; Magi-Galluzzi C; Jones JS
    J Urol; 2008 May; 179(5):1746-50; discussion 1750. PubMed ID: 18343412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for preoperative prostate biopsy in patients undergoing radical cystoprostatectomy for bladder cancer.
    Thomas C; Wiesner C; Melchior S; Gillitzer R; Schmidt F; Thüroff JW
    J Urol; 2008 Nov; 180(5):1938-41; discussion 1941. PubMed ID: 18801501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate specific antigen velocity in men with total prostate specific antigen less than 4 ng/ml.
    Loeb S; Roehl KA; Nadler RB; Yu X; Catalona WJ
    J Urol; 2007 Dec; 178(6):2348-52; discussion 2352-3. PubMed ID: 17936844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A framework for the identification of men at increased risk for prostate cancer.
    Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL
    J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K; Raaijmakers R; Roobol M; Wildhagen M; Yamanaka H; Schröder FH
    Cancer; 2005 Jan; 103(2):242-50. PubMed ID: 15578715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate cancers diagnosed at repeat biopsy are smaller and less likely to be high grade.
    Tan N; Lane BR; Li J; Moussa AS; Soriano M; Jones JS
    J Urol; 2008 Oct; 180(4):1325-9; discussion 1329. PubMed ID: 18707706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting the risk of patients with biopsy Gleason score 6 to harbor a higher grade cancer.
    Gofrit ON; Zorn KC; Taxy JB; Lin S; Zagaja GP; Steinberg GD; Shalhav AL
    J Urol; 2007 Nov; 178(5):1925-8. PubMed ID: 17868725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less.
    Morgentaler A; Rhoden EL
    Urology; 2006 Dec; 68(6):1263-7. PubMed ID: 17169647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
    J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate specific antigen velocity threshold for predicting prostate cancer in young men.
    Loeb S; Roehl KA; Catalona WJ; Nadler RB
    J Urol; 2007 Mar; 177(3):899-902. PubMed ID: 17296371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
    Thompson IM; Tangen CM; Goodman PJ; Lucia MS; Parnes HL; Lippman SM; Coltman CA
    J Urol; 2007 May; 177(5):1749-52. PubMed ID: 17437804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass screening for prostate cancer in Korea: a population based study.
    Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
    J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
    Schröder FH; Roobol MJ; Andriole GL; Fleshner N
    J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal PSA changes in men with and without prostate cancer: assessment of prostate cancer risk.
    Berger AP; Deibl M; Steiner H; Bektic J; Pelzer A; Spranger R; Klocker H; Bartsch G; Horninger W
    Prostate; 2005 Aug; 64(3):240-5. PubMed ID: 15712213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.